




Searching News Database: Anturol
HSMN NewsFeed - 8 Dec 2011
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
HSMN NewsFeed - 4 Aug 2011
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
HSMN NewsFeed - 11 Jul 2011
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
HSMN NewsFeed - 8 Jul 2009
Antares Pharma Promotes Robert F. Apple, Dr. Kaushik Dave and Dr. Peter Sadowski
Antares Pharma Promotes Robert F. Apple, Dr. Kaushik Dave and Dr. Peter Sadowski
HSMN NewsFeed - 13 Oct 2008
Antares Pharma Appoints Paul K. Wotton, Ph.D., as President and Chief Executive Officer
Antares Pharma Appoints Paul K. Wotton, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 23 Aug 2007
Antares Announces Initiation of Pivotal Trial of ANTUROL(TM) for the Treatment of Overactive Bladder
Antares Announces Initiation of Pivotal Trial of ANTUROL(TM) for the Treatment of Overactive Bladder
HSMN NewsFeed - 25 Jul 2007
Antares Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Trial of Anturol(TM)
Antares Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Trial of Anturol(TM)
HSMN NewsFeed - 19 Apr 2007
Antares Pharma Announces Positive Results from Application Site Study for ANTUROL(R)
Antares Pharma Announces Positive Results from Application Site Study for ANTUROL(R)
Additional items found! 2

Members Archive contains
2 additional stories matching:
Anturol
(Password required)
Anturol
(Password required)